Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tomohiro Nishina
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of Two Randomized Clinical Trials
Clinical Colorectal Cancer
Oncology
Gastroenterology
P1-060a Phase II Study of Nab-PTX in Combination With RAM in Patients With Pre-Treated AGC: Results of Final Analysis
Annals of Oncology
Medicine
Oncology
Hematology
Related publications
A Retrospective Study of Trifluridine/Tipiracil in Pretreated Metastatic Colorectal Cancer Patients in Clinical Practice
Colorectal Cancer
Oncology
Gastroenterology
Emerging Combination Therapies for Metastatic Colorectal Cancer &Ndash; Impact of Trifluridine/Tipiracil
Cancer Management and Research
Oncology
Review of Metastatic Colorectal Cancer Treatment Pathways and Early Clinical Experience of Trifluridine/Tipiracil in the UK Named Patient Programme
BMC Cancer
Cancer Research
Oncology
Genetics
Cost Effectiveness of Trifluridine/Tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
Clinical Colorectal Cancer
Oncology
Gastroenterology
Duration of Previous Treatment as a Prognostic Factor in Metastatic Colorectal Cancer Treated With Trifluridine/Tipiracil
Molecular and Clinical Oncology
Cancer Research
Oncology
Cytotoxicity of Trifluridine Correlates With the Thymidine Kinase 1 Expression Level
Scientific Reports
Multidisciplinary
Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib
Oncologist
Cancer Research
Medicine
Oncology
Mutation Analysis in the Coding Sequence of Thymidine Kinase 1 in Breast and Colorectal Cancer
International Journal of Biological Markers
Oncology
Cancer Research
Clinical Biochemistry
Forensic Medicine
Medicine
Pathology
Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials
Oncotarget
Oncology
